First Wave BioPharma Stock Jumps On Niclosamide's Favorable Safety Profile In COVID-19 Related GI Infections

by Vandana Singh, Benzinga Editor

November 30, 2021 8:33 AM | 1 min read |

The independent data monitoring committee (DMC) has recommended First Wave BioPharma Inc FWBI to continue enrollment in Part 2 of the RESERVOIR Phase 2 trial evaluating FW-COV for COVID-19-related gastrointestinal (GI) infections.
FW-COV is a proprietary, oral tablet formulation of micronized niclosamide developed to remove SARS-CoV-2 from the GI tract.
The DMC recommendation was based on the safety data collected from the first 25 patients enrolled in Part 2 of the RESERVOIR trial.
The review of the data uncovered no safety issues. Part 2 of the study will enroll up to 150 patients.
Price Action: FWBI shares are up 38.6% at $2.62 during the premarket session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.